This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

PGx Study to Develop and Validate the Predictive Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jae-Gook Shin, Inje University
ClinicalTrials.gov Identifier:
NCT01178502
First received: August 9, 2010
Last updated: May 30, 2013
Last verified: May 2013
  Purpose
To develop and validate the predictive warfarin dosing algorithm.

Condition
Heart Valve Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Warfarin Dosing Algorithm for Personalized Warfarin Pharmacotherapy in Korean Patients

Resource links provided by NLM:


Further study details as provided by Jae-Gook Shin, Inje University:

Primary Outcome Measures:
  • To Develop and Validate the Predictive Warfarin Dosing Algorithm [ Time Frame: 1 year ]

Biospecimen Retention:   Samples With DNA
Blood samples were taken from patients for genotyping about 8ml

Enrollment: 405
Study Start Date: March 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Detailed Description:
This study aims to develop and validate the predictive warfarin dosing algorithm for personalized warfarin pharmacotherapy in Korean patients.
  Eligibility

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
the patients taking warfarin
Criteria

Inclusion Criteria:

  • the patients taking warfarin

Exclusion Criteria:

  • noncompliance
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01178502

Locations
Korea, Republic of
Inje University
Busan, Korea, Republic of, 614-735
Sponsors and Collaborators
Inje University
  More Information

Responsible Party: Jae-Gook Shin, Department of Pharmacology and Pharmacogenomics Research Center, Inje University
ClinicalTrials.gov Identifier: NCT01178502     History of Changes
Other Study ID Numbers: 09-025
Study First Received: August 9, 2010
Last Updated: May 30, 2013

Additional relevant MeSH terms:
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Warfarin
Anticoagulants

ClinicalTrials.gov processed this record on September 21, 2017